Pharmaids Pharmaceuticals Ltd.

62.96 +2.99 ▲5.0%

16 April 2024, 01:33:00 PM
Volume: 16,739

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.pharmaids.com
Market Cap 222.05 Cr.
Enterprise Value(EV) 211.50 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -2.72 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 40.96 Trailing Twelve Months Ending 2023-12
Book Value / Share 20.55 Trailing Twelve Months Ending 2023-12
Price to Book Value 3.06 Calculated using Price: 62.96
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 3.53 Cr. 35,267,812 Shares
FaceValue 10
About Pharmaids Pharmaceuticals Ltd.
The Company is engaged in the business of Trading and Manufacturing of Generics, Bulk Drugs and Intermediaries, etc.

Pharmaids Pharmaceuticals Ltd. Delivery

Delivered Qty
Traded Qty

Pharmaids Pharmaceuticals Ltd. Performance

1 Day
+4.99%
1 Week
+18.46%
1 Month
+18.19%
3 Month
-7.56%
6 Month
+40.29%
1 Year
+219.76%
2 Year
+325.41%
5 Year
+1236.73%
10 Year
+2312.26%

Pharmaids Pharmaceuticals Ltd. Fundamental Ratios

2 years 2022-03 2023-03
Return on Equity (%) 1.67 -49.28
Return on Capital Employed (%) 1.65 -63.87
Return on Assets (%) 1.35 -46.3

Pharmaids Pharmaceuticals Ltd. Balance Sheet

Particulars 3 years 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 9 22 21
Non Curr. Liab. 0 -3 -3
Curr. Liab. 2 2 0
Minority Int.
Equity & Liab. 11 22 17
Non Curr. Assets 8 4 16
Curr. Assets 3 18 1
Misc. Exp. not W/O 0
Total Assets 11 22 17

Pharmaids Pharmaceuticals Ltd. Profit and Loss

Particulars 3 years 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 4 0
Other Income 0 -1
Total Income 4 -1
Total Expenditure -4 -10 -13
PBIDT 0 -10 -13
Interest
Depreciation 0 0 0
Taxation 2 4
Exceptional Items
PAT 0 -8 -10
Minority Interest
Share Associate 0
Other Related Items 0
Consolidated Net Profit 0 -8 -10
Adjusted EPS 0 -4 -4

Pharmaids Pharmaceuticals Ltd. Cash Flow

Particulars 2 years 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 -4
Cash Fr. Inv. 0 -5
Cash Fr. Finan. 21
Net Change 0 12
Cash & Cash Eqvt 0 13

Pharmaids Pharmaceuticals Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 55.56 35.44 20.70 20.97 16.52 9.95 9.94 9.70 9.25
Public 44.44 64.56 79.30 79.03 83.48 90.05 90.06 90.30 90.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Pharmaids Pharmaceuticals Ltd. Announcements

Wed, 10 Apr 2024
Compliance Certificate Under Regulation 7(3) Of SEBI Listing Regulations 2015 For The Year Ended 31St March 2024.
Compliance certificate as required under regulation 7(3) of SEBI Listing Regulations 2015 for the year ended 31st March 2024.
Wed, 10 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyPHARMAIDS PHARMACEUTICALS LTD.
2CIN NO.L52520KA1989PLC173979
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Kaushik Kumar
Designation: Company Secretary Compliance Officer and Head Legal
EmailId: kaushik@pharmaids.com
Name of the Chief Financial Officer: Balagangadhara B C
Designation: Chief Financial Officer
EmailId: bg@pharmaids.com

Date: 10/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Mon, 08 Apr 2024
Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended 31St March 2024.
Pursuant to Regulation 40(9) of SEBI (Listing Obligations and Dislcosure Requirement) Regulations 2015 we are enclosing herewith a certificate obtained from PCS for the period covering from 01st April 2023 to 31st March 2024.

Pharmaids Pharmaceuticals Ltd. Technical Scans

Mon, 15 Apr 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at High Opening at High
Closing Above Previous High Closing Above Previous High

Pharmaids Pharmaceuticals Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 369,773.51 1,532.25 -0.5%
Cipla Ltd. 111,517.58 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. 100,257.78 6,030.60 +0.3%
Divi's Laboratories Ltd. 98,636.18 3,770.20 +1.4%
Zydus Lifesciences Ltd. 94,082.88 950.25 +1.6%
Mankind Pharma Ltd. 90,721.26 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. 90,631.78 6,281.45 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.52 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-12 30.07 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.18 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-12 71.32 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.64 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-12 52.53 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 114.82 6,281.45 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.93 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-12 4.31 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.73 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-12 7.57 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.99 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-12 10.21 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.42 6,281.45 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-03 0.02 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,281.45 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,281.45 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,281.45 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,281.45 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,532.25 -0.5%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,381.00 0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,030.60 +0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,770.20 +1.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 950.25 +1.6%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,298.50 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,281.45 -0.3%

Pharmaids Pharmaceuticals Ltd. FAQ's

What is Pharmaids Pharma share price?

Can I buy Pharmaids Pharma shares now?

What is the Market Cap of Pharmaids Pharma?

What are the key metrics to analyse Pharmaids Pharma?

What is the 52 Week High and Low of Pharmaids Pharma?

What is the trend of Pharmaids Pharma share price?